Catalog Products » MMP-9, His, Cynomolgus
Manual
Manual
COAs

MMP-9, His, Cynomolgus

Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14.
$390.00
Z04875-100

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
MMP-9 (Ala20-Asp706)
Accession # A0A2K5UU71		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 77.44 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 85-100 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

MMP-9, His, Cynomolgus

Immobilized MMP-9, His, Cynomolgus, His Tag at 0.5 μg /ml (100 μl /well) on the plate. Dose response curve for Anti-MMP-9 Antibody, hFc Tag with the EC50 of 13.2ng/ml determined by ELISA. »

MMP-9, His, Cynomolgus

The purity of MMP-9, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »

MMP-9, His, Cynomolgus

MMP-9, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14.
Synonyms MMP-9; GELB; CLG4B; MANDP2; Gelatinase B
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.